Four recent deals fueled more angst about China’s biotech progress, while Pfizer, Bristol Myers and Sarepta all worked to ...

Now, it’s worth noting Stock Advisor’s total average return is 971 % — a market-crushing outperformance compared to 196% for ...

Pfizer on Tuesday joined the cavalcade of big pharma firms hunting for novel weight loss drugs in the laboratories of Chinese biotechs, even as U.S. authorities ramp up efforts to undercut the growing ...

Pfizer recently announced its guidance for 2026. One thing seems clear: Its financial results won't get much stronger. It ...